According to this newly revised definition, "An individual with biomarker evidence of Aβ deposition (e.g. abnormal amyloid PET scan) with an evidence of pathologic tau biomarker would be assigned the label Alzheimer’s disease". The gene discussed is MAPT; the disease is early-onset autosomal dominant Alzheimer disease.